1. Home
  2. MERC vs XLO Comparison

MERC vs XLO Comparison

Compare MERC & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

HOLD

Current Price

$0.73

Market Cap

60.2M

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$9.00

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MERC
XLO
Founded
1968
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.2M
49.8M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
MERC
XLO
Price
$0.73
$9.00
Analyst Decision
Hold
Buy
Analyst Count
3
1
Target Price
$2.25
$28.00
AVG Volume (30 Days)
384.5K
27.3K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
7.01%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,169,145,000.00
$43,766,000.00
Revenue This Year
$13.75
N/A
Revenue Next Year
$10.12
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
25.50
589.88
52 Week Low
$0.71
$0.46
52 Week High
$4.47
$9.30

Technical Indicators

Market Signals
Indicator
MERC
XLO
Relative Strength Index (RSI) 34.23 65.15
Support Level N/A $7.47
Resistance Level $1.06 $8.97
Average True Range (ATR) 0.08 0.50
MACD -0.01 0.09
Stochastic Oscillator 8.90 81.49

Price Performance

Historical Comparison
MERC
XLO

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: